• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Applied DNA Sciences Inc. filed SEC Form 8-K: Leadership Update

    11/10/25 5:01:29 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    false 0000744452 0000744452 2025-11-06 2025-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT 

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): November 6, 2025

      

    Applied DNA Sciences, Inc.

    (Exact name of registrant as specified in its charter)

      

    Delaware

    (State or other jurisdiction

    of incorporation or organization)

    001-36745

    (Commission File Number)

    59-2262718

    (IRS Employer

    Identification No.)

     

    50 Health Sciences Drive

    Stony Brook, New York 11790

    (Address of principal executive office) (Zip Code)

      

    631-240-8800

    (Registrants’ telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 par value   BNBX   The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

     

    Emerging Growth Company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

      

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On November 6, 2025, the Board of Directors (the “Board”) of Applied DNA Sciences, Inc. (the “Company”), upon recommendation of the Nominating Committee of the Board, appointed Joshua Kruger to serve as its Chairman and as a director. At the time of Mr. Kruger’s appointment, the Board had a vacancy as the result of the previously disclosed resignation on September 29, 2025 of Sanford R. Simon. Mr. Kruger replaced Judith Murrah as Chairman, who voluntarily resigned from her position as Chairperson of the Board effective November 6, 2025. Ms. Murrah will continue to serve as a director of the Company. Ms. Murrah’s resignation as Chairperson is not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.

     

    The Board has determined that Mr. Kruger does not satisfy the independence criteria set forth in the Nasdaq rules and is not “independent” for purposes of serving on the Board. For his services as Chairman, Mr. Kruger is expected to receive the same annual compensation as the Company’s other non-employee directors, if any. In connection with Mr. Kruger’s appointment to the Board, the Company will enter into its standard form of indemnification agreement for directors and officers (the “Indemnification Agreement”) with Mr. Kruger. Pursuant to the terms of the Indemnification Agreement, the Company may be required, among other things, to indemnify Mr. Kruger for certain expenses, including reasonable attorneys’ fees, retainers, court costs, transcripts, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses incurred by him in any action, proceeding or appeal arising out of his service on the Board or in connection with establishing or enforcing a right to indemnification.

     

    Mr. Kruger is an affiliate of Cypress Management LLC, a Puerto Rico limited liability company (the “Strategic Advisor”), and of Cypress LLC, a Puerto Rico limited liability company (the “Services Provider”). Mr. Kruger has an approximately 33% economic interest in each of the Strategic Advisor and the Services Provider. As previously disclosed, on September 29, 2025, the Company entered into a Strategic Advisor Agreement (the “Strategic Advisor Agreement”) with the Strategic Advisor, pursuant to which the Company engaged the Strategic Advisor to provide strategic advice, guidance and technical advisory services relating to the Company’s business, operations, growth initiatives and industry trends in the crypto technology sector. Pursuant to the terms of the Strategic Advisor Agreement, the Company pays a monthly fee of $60,000 to the Strategic Advisor and, in connection with the private placement offerings of the Company’s common stock, par value $0.001 per share (the “Common Stock”), which closed on October 3, 2025 and October 22, 2025 (collectively, the “Offering”), issued to the Strategic Advisor five year warrants to purchase 1,986,634 shares of Common Stock. In the Offering, Mr. Kruger also individually purchased 75,302 shares of Common Stock and warrants to purchase 75,302 shares of Common Stock for an aggregate purchase price of $250,002.64.

     

    Also as previously disclosed, on September 29, 2025, the Company entered into a Strategic Digital Assets Services Agreement (the “Strategic DAS Agreement”) with the Services Provider, pursuant to which the Company appointed the Services Provider to provide discretionary asset management services (i) in compliance with the Company’s BNB-focused treasury strategy and (ii) with respect to any other cryptocurrency or digital asset strategies subject to the Company’s approval, in each case, solely with respect to the Account Assets (as defined in the Strategic DAS Agreement) in the accounts or cryptocurrency “wallets” identified by the Company after consultation with the Services Provider (collectively, the “Account”). Pursuant to the Strategic DAS Agreement, the Company pays to the Services Provider a fixed-rate management fee accrued and payable monthly (prorated for partial months) in arrears, equal to 1/12 of 1.25% per annum multiplied by the net asset value of the Account as of the last day of each month, before taking into account the estimated accrued incentive fee (as described below), if any. The management fee is payable within fifteen days of the Company’s receipt of an invoice from the Services Provider after the end of each month. In addition, the Company pays to the Services Provider an incentive fee for each Incentive Period (as defined in the Strategic DAS Agreement) relating to the Account equal to 10% on net returns, multiplied by the amount, if any, by which the increase in net asset value of the Account during such Incentive Period (excluding any amounts contributed to or withdrawn from the Account during such Incentive Period) exceeds the sum of (x) net asset value for the Account as of the later of the effective date of September 29, 2025 and the last time an incentive fee was paid in respect of the Account and (y) the aggregate management fees, to the extent not included in the calculation of net asset value, to Services Provider during such Incentive Period.

     

    The foregoing description of the Indemnification Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of such agreement, which was previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed by the Company on September 13, 2012 and is incorporated herein by reference. The foregoing descriptions of the Strategic DAS Agreement and the Strategic Advisor Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which were previously filed as Exhibits 10.5 and 10.6, respectively, to the Current Report on Form 8-K filed by the Company on October 1, 2025 and are incorporated herein by reference.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

      APPLIED DNA SCIENCES, INC.
         
    Dated: November 10, 2025 By: /s/ Clay Shorrock
      Name: Clay Shorrock
      Title: Chief Executive Officer

     

     

    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Applied DNA Sciences Inc.

    SCHEDULE 13G/A - BNB PLUS CORP. (0000744452) (Subject)

    11/14/25 8:14:14 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    11/10/25 5:01:29 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form DEF 14A filed by Applied DNA Sciences Inc.

    DEF 14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    11/10/25 4:55:23 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ceccoli Joseph D. was granted 22,511 shares, increasing direct ownership by 2,251,100% to 22,512 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:06:16 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Chief Financial Officer Jantzen Beth was granted 18,691 shares, increasing direct ownership by 623,033% to 18,694 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:03:14 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Director Murrah Judith was granted 18,691 shares, increasing direct ownership by 623,033% to 18,694 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:00:49 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation

    Appoints TradFi and DeFi Leaders as Advisers, Including Anthony Scaramucci Enhanced Staking and Yield Strategy Focused on BNB Native Yield Integrating DeFi and Binance Ecosystem Expertise Offering Led by Institutional and Crypto-Native Investors including Galaxy, Off The Chain, Silvermine and Gaia Digital Assets Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity ("PIPE") offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurren

    9/29/25 3:08:00 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

    - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

    1/10/25 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

    2/11/22 6:29:21 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

    8/13/21 6:30:16 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

    4/22/21 6:37:35 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    View All

    Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

    Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

    9/6/23 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

    STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

    4/1/21 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

    STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

    12/16/24 10:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

    STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

    8/7/24 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/13/24 4:15:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/7/24 10:11:34 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary